DexCom (DXCM) Competitors

DexCom logo
$81.61 -1.72 (-2.06%)
Closing price 04:00 PM Eastern
Extended Trading
$80.64 -0.97 (-1.19%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DXCM vs. HQY, PODD, ABT, AMN, and ITGR

Should you buy DexCom stock or one of its competitors? DexCom's main competitors and comparable companies include HealthEquity (HQY), Insulet (PODD), Abbott Laboratories (ABT), AMN Healthcare Services (AMN), and Integer (ITGR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does DexCom compare to HealthEquity?

DexCom (NASDAQ:DXCM) and HealthEquity (NASDAQ:HQY) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

DexCom has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, HealthEquity has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market.

In the previous week, DexCom had 6 more articles in the media than HealthEquity. MarketBeat recorded 8 mentions for DexCom and 2 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.63 beat DexCom's score of 0.96 indicating that HealthEquity is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DexCom
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
HealthEquity
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

DexCom has higher revenue and earnings than HealthEquity. DexCom is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DexCom$4.66B6.67$836.30M$2.5532.68
HealthEquity$1.36B6.28$215.20M$2.7737.35

DexCom currently has a consensus target price of $95.50, indicating a potential upside of 14.60%. HealthEquity has a consensus target price of $113.53, indicating a potential upside of 9.74%. Given DexCom's stronger consensus rating and higher possible upside, research analysts plainly believe DexCom is more favorable than HealthEquity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DexCom
0 Sell rating(s)
2 Hold rating(s)
24 Buy rating(s)
2 Strong Buy rating(s)
3.00
HealthEquity
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.92

97.8% of DexCom shares are owned by institutional investors. Comparatively, 99.6% of HealthEquity shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 1.6% of HealthEquity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

DexCom has a net margin of 19.42% compared to HealthEquity's net margin of 17.36%. DexCom's return on equity of 37.77% beat HealthEquity's return on equity.

Company Net Margins Return on Equity Return on Assets
DexCom19.42% 37.77% 15.98%
HealthEquity 17.36%15.33%9.51%

Summary

DexCom beats HealthEquity on 12 of the 17 factors compared between the two stocks.

How does DexCom compare to Insulet?

Insulet (NASDAQ:PODD) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

97.8% of DexCom shares are owned by institutional investors. 0.4% of Insulet shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Insulet presently has a consensus target price of $185.67, suggesting a potential upside of 21.76%. DexCom has a consensus target price of $95.50, suggesting a potential upside of 14.60%. Given Insulet's higher probable upside, equities research analysts clearly believe Insulet is more favorable than DexCom.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insulet
1 Sell rating(s)
12 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.44
DexCom
0 Sell rating(s)
2 Hold rating(s)
24 Buy rating(s)
2 Strong Buy rating(s)
3.00

Insulet has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, DexCom has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

DexCom has a net margin of 19.42% compared to Insulet's net margin of 13.44%. DexCom's return on equity of 37.77% beat Insulet's return on equity.

Company Net Margins Return on Equity Return on Assets
Insulet13.44% 31.76% 14.48%
DexCom 19.42%37.77%15.98%

In the previous week, Insulet had 6 more articles in the media than DexCom. MarketBeat recorded 14 mentions for Insulet and 8 mentions for DexCom. DexCom's average media sentiment score of 0.96 beat Insulet's score of 0.81 indicating that DexCom is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Insulet
5 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
DexCom
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

DexCom has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insulet$2.71B3.91$247.10M$6.1424.83
DexCom$4.66B6.67$836.30M$2.5532.68

Summary

DexCom beats Insulet on 13 of the 17 factors compared between the two stocks.

How does DexCom compare to Abbott Laboratories?

DexCom (NASDAQ:DXCM) and Abbott Laboratories (NYSE:ABT) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

DexCom has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Abbott Laboratories has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

DexCom presently has a consensus price target of $95.50, indicating a potential upside of 14.60%. Abbott Laboratories has a consensus price target of $118.32, indicating a potential upside of 8.96%. Given DexCom's stronger consensus rating and higher possible upside, research analysts clearly believe DexCom is more favorable than Abbott Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DexCom
0 Sell rating(s)
2 Hold rating(s)
24 Buy rating(s)
2 Strong Buy rating(s)
3.00
Abbott Laboratories
0 Sell rating(s)
5 Hold rating(s)
21 Buy rating(s)
2 Strong Buy rating(s)
2.89

Abbott Laboratories has higher revenue and earnings than DexCom. DexCom is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DexCom$4.66B6.67$836.30M$2.5532.68
Abbott Laboratories$44.33B4.24$6.52B$2.6840.52

97.8% of DexCom shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

DexCom has a net margin of 19.42% compared to Abbott Laboratories' net margin of 9.75%. DexCom's return on equity of 37.77% beat Abbott Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
DexCom19.42% 37.77% 15.98%
Abbott Laboratories 9.75%18.04%9.09%

In the previous week, Abbott Laboratories had 16 more articles in the media than DexCom. MarketBeat recorded 24 mentions for Abbott Laboratories and 8 mentions for DexCom. Abbott Laboratories' average media sentiment score of 1.30 beat DexCom's score of 0.96 indicating that Abbott Laboratories is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DexCom
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Abbott Laboratories
18 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

DexCom beats Abbott Laboratories on 9 of the 16 factors compared between the two stocks.

How does DexCom compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and DexCom (NASDAQ:DXCM) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

AMN Healthcare Services currently has a consensus target price of $39.17, indicating a potential upside of 2.94%. DexCom has a consensus target price of $95.50, indicating a potential upside of 14.60%. Given DexCom's stronger consensus rating and higher probable upside, analysts clearly believe DexCom is more favorable than AMN Healthcare Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AMN Healthcare Services
1 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.33
DexCom
0 Sell rating(s)
2 Hold rating(s)
24 Buy rating(s)
2 Strong Buy rating(s)
3.00

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AMN Healthcare Services has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, DexCom has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

In the previous week, AMN Healthcare Services and AMN Healthcare Services both had 8 articles in the media. DexCom's average media sentiment score of 0.96 beat AMN Healthcare Services' score of 0.47 indicating that DexCom is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AMN Healthcare Services
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
DexCom
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

DexCom has a net margin of 19.42% compared to AMN Healthcare Services' net margin of 3.10%. DexCom's return on equity of 37.77% beat AMN Healthcare Services' return on equity.

Company Net Margins Return on Equity Return on Assets
AMN Healthcare Services3.10% 23.42% 7.19%
DexCom 19.42%37.77%15.98%

DexCom has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AMN Healthcare Services$2.73B0.54-$95.70M$2.7513.84
DexCom$4.66B6.67$836.30M$2.5532.68

Summary

DexCom beats AMN Healthcare Services on 13 of the 16 factors compared between the two stocks.

How does DexCom compare to Integer?

DexCom (NASDAQ:DXCM) and Integer (NYSE:ITGR) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

DexCom currently has a consensus price target of $95.50, indicating a potential upside of 14.60%. Integer has a consensus price target of $113.67, indicating a potential downside of 10.25%. Given DexCom's stronger consensus rating and higher probable upside, research analysts clearly believe DexCom is more favorable than Integer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DexCom
0 Sell rating(s)
2 Hold rating(s)
24 Buy rating(s)
2 Strong Buy rating(s)
3.00
Integer
0 Sell rating(s)
11 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.08

DexCom has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Integer has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

In the previous week, DexCom had 6 more articles in the media than Integer. MarketBeat recorded 8 mentions for DexCom and 2 mentions for Integer. Integer's average media sentiment score of 1.88 beat DexCom's score of 0.96 indicating that Integer is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DexCom
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Integer
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

DexCom has higher revenue and earnings than Integer. DexCom is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DexCom$4.66B6.67$836.30M$2.5532.68
Integer$1.85B2.32$102.81M$2.9842.50

DexCom has a net margin of 19.42% compared to Integer's net margin of 5.68%. DexCom's return on equity of 37.77% beat Integer's return on equity.

Company Net Margins Return on Equity Return on Assets
DexCom19.42% 37.77% 15.98%
Integer 5.68%11.84%5.98%

97.8% of DexCom shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 1.1% of Integer shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

DexCom beats Integer on 12 of the 17 factors compared between the two stocks.

Get DexCom News Delivered to You Automatically

Sign up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DXCM vs. The Competition

MetricDexComHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$30.35B$5.97B$7.83B$11.75B
Dividend YieldN/A1.68%2.47%4.41%
P/E Ratio30.4839.0934.3430.11
Price / Sales6.534.848.005.34
Price / Cash29.4024.1821.0222.34
Price / Book12.004.954.763.85
Net Income$836.30M$143.12M$3.52B$393.14M
7 Day Performance0.67%-4.86%-5.34%-4.53%
1 Month Performance-5.15%-2.87%-3.61%-5.86%
1 Year Performance40.56%-0.76%0.01%-7.78%

DexCom Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXCM
DexCom
3.7763 of 5 stars
$81.61
-2.1%
$95.50
+17.0%
+43.5%$30.35B$4.66B30.4811,000
HQY
HealthEquity
3.6 of 5 stars
$102.11
-1.5%
$113.53
+11.2%
+1.7%$8.45B$1.31B36.862,814
PODD
Insulet
4.3926 of 5 stars
$149.81
+2.3%
$185.67
+23.9%
-54.2%$10.39B$3.19B24.405,400
ABT
Abbott Laboratories
4.3369 of 5 stars
$110.41
+0.4%
$118.32
+7.2%
-16.8%$191.04B$48.23B41.20115,000
AMN
AMN Healthcare Services
1.9914 of 5 stars
$38.00
+5.0%
$39.17
+3.1%
+140.4%$1.47B$3.43B13.822,664

Related Companies and Tools


This page (NASDAQ:DXCM) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners